Page 36 - Merck Sharp News Today

Capivasertib plus fulvestrant provided a clinically meaningful improvement in progression-free survival over fulvestrant alone in patients with hormone receptor–positive advanced breast cancer, including those who previously received a CDK4/6 inhibitor, chemotherapy in the advanced setting, or had baseline liver metastases.

Q1 Presentation May 12, 2023 Forward-looking statement ... | May 12, 2023

Check out the list of the top healthcare governCheck out the list of the top healthcare government contractors to watch out for in 2023.ment contractors to watch out for in 2023.

The Pharmaceutical Journal from the Royal Pharmaceutical Society

The annual meeting of the American Association for Cancer Research was held this year from April 14 to 19 in Orlando, Florida, and attracted approximately 19,000 participants from around the world, including scientists, cancer survivors, clinicians, allied health professionals, and industry professionals. The conference highlighted recent advances in the treatment, management, and prevention of cancer.

The PD-1 and PD-L1 inhibitors market is anticipated to be driven in the coming years due to the rise in novel drugs and therapies and the increase in healthcare spending across the world. In

Researchers are conducting a phase 2 trial of docetaxel and pembrolizumab in combination with IL-12 gene therapy for triple-negative breast cancer.

Eric A. Singer, MD, discusses the findings from cohort B of KEYNOTE-057 and explains why systemic therapy with pembrolizumab could be beneficial for patients with Bacillus Calmette-Guérin–unresponsive, high-risk, papillary-only non–muscle invasive bladder cancer who hope to avoid radical cystectomy.

Irvine’s Urovant Sciences Ltd., which at one time was preparing to explode to almost a billion dollars in annual sales of medication to treat overactive bladders, is being folded into the U.S. operations of giant Japanese pharmaceutical firm Sumitomo Pharma Co. Ltd.

Children with bronchiolitis before the age of 2 years had a substantially greater risk for pediatric asthma and recurrent wheezing.